An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Novaferon (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational
- Sponsors Genova Biotech Company
Most Recent Events
- 03 Jan 2022 New trial record